Fortunato Ciardiello

发表

Delivering precision medicine in oncology today and in future-the promise and challenges of personalised cancer medicine: a position paper by the European Society for Medical Oncology (ESMO).

M. Piccart, K. Mcgregor, R. Stahel, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Tumor-intrinsic expression of the autophagy gene Atg16l1 suppresses anti-tumor immunity in colorectal cancer

James Ziai, S. Jhunjhunwala, F. D. de Sauvage, 2023, Nature communications.

Interactions between the epidermal growth factor receptor and type I protein kinase A: biological significance and therapeutic implications.

G. Tortora, F. Ciardiello, Fortunato Ciardiello, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS-mutated metastatic colorectal cancer

E. Van Cutsem, J. Tabernero, F. Ciardiello, 2015, British Journal of Cancer.

Cetuximab administered once every second week to patients with metastatic colorectal cancer: a two-part pharmacokinetic/pharmacodynamic phase I dose-escalation study.

F. J. Ramos, J. Baselga, J. Tabernero, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Interaction between the epidermal growth factor receptor (EGFR) and the vascular endothelial growth factor (VEGF) pathways: a rational approach for multi-target anticancer therapy.

G. Tortora, F. Ciardiello, R. Bianco, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Intrinsic resistance to selumetinib, a selective inhibitor of MEK1/2, by cAMP-dependent protein kinase A activation in human lung and colorectal cancer cells

M. Caraglia, E. Van Cutsem, F. Ciardiello, 2012, British Journal of Cancer.

8-chloro-cAMP inhibits smooth muscle cell proliferation in vitro and neointima formation induced by balloon injury in vivo.

C. Indolfi, D. Torella, A. Leccia, 2000, Journal of the American College of Cardiology.

Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial.

G. Botti, N. Normanno, F. Fenizia, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next-generation sequencing: findings from the CAPRI-GOIM trial.

G. Botti, N. Normanno, F. Fenizia, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Preclinical Activity of the Rational Combination of Selumetinib (azd6244) in Combination with Vorinostat in Kras Mutant Colorectal Cancer Models

M. Hidalgo, A. Tan, F. Ciardiello, 2022 .

The current and future role of the medical oncologist in the professional care for cancer patients: a position paper by the European Society for Medical Oncology (ESMO).

J. Douillard, E. Cutsem, K. Fumasoli, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancer

C. Gridelli, T. Troiani, G. Catalano, 2006, British Journal of Cancer.

Antitumor activity of dual blockade of PD-L1 and MEK in NSCLC patients derived three-dimensional spheroid cultures

S. Zappavigna, M. Caraglia, A. Fiorelli, 2019, Journal of Experimental & Clinical Cancer Research.

Therapeutic integration of signal transduction targeting agents and conventional anti-cancer treatments.

G. Tortora, F. Ciardiello, D. Melisi, 2004, Endocrine-related cancer.

Targeting EGFR in pancreatic cancer treatment.

F. Ciardiello, T. Troiani, E. Martinelli, 2012, Current drug targets.

Optimising translational oncology in clinical practice: strategies to accelerate progress in drug development.

C. Sotiriou, M. Piccart, P. Laurent-Puig, 2015, Cancer treatment reviews.

643PCELL GROWTH INHIBITION OF HER2 POSITIVE TRASTUZUMAB RESISTANT GASTRIC CANCER CELL LINES BY COMBINED INHIBITION OF PI3K/AKT/MTOR AND MAPK.

T. Troiani, G. Martini, E. Martinelli, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Detection of erbB2 copy number variations in plasma of patients with esophageal carcinoma

A. Iolascon, I. Andolfo, Pasqualino de Antonellis, 2011, BMC Cancer.

Regorafenib-associated hand–foot skin reaction: practical advice on diagnosis, prevention, and management

M. Lacouture, E. Van Cutsem, F. Ciardiello, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Efficacy and safety results from IMblaze370, a randomised Phase III study comparing atezolizumab+cobimetinib and atezolizumab monotherapy vs regorafenib in chemotherapy-refractory metastatic colorectal cancer.

J. Tabernero, N. Segal, M. Fakih, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Interactions between the epidermal growth factor receptor and type I protein kinase A: biological significance and therapeutic implications.

Fortunato Ciardiello, G. Tortora, F. Ciardiello, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

Neo-adjuvant and adjuvant chemotherapy of gastric cancer.

F. Ciardiello, G. Catalano, G. Santabarbara, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

Sorafenib in combination with erlotinib or with gemcitabine in elderly patients with advanced non-small-cell lung cancer: a randomized phase II study.

A. Chella, C. Gridelli, F. de Marinis, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.